Login to Your Account

Micurx Reaps $25M for Antimicrobials

By Marie Powers
Staff Writer

Friday, August 23, 2013
Antimicrobial developer Micurx Pharmaceuticals Inc. raised $25 million in a Series B to fund the U.S. development of MRX-I, its oral oxazolidinone antibiotic targeting infections from multidrug-resistant gram-positive bacteria, including methicillin-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococci (VRE).

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription